Verona Pharma plc Verona Pharma To Attend Btig Biotechnology Conference 2019 And Present At 2019 Wedbush Pacgrow Healthcare C...
July 24 2019 - 2:00AM
UK Regulatory
TIDMVRP
LONDON, July 24, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on respiratory diseases, today announces that the
Company's management team will conduct face-to-face meetings at the BTIG
Biotechnology Conference 2019, and will present at the 2019 Wedbush
PacGrow Healthcare Conference.
Conference: BTIG Biotechnology Conference 2019
Attendees: Jan-Anders Karlsson, PhD, CEO, and Piers Morgan, CFO
Date: Monday, August 12th
Location: New York, NY
Conference: 2019 Wedbush PacGrow Healthcare Conference
Presenter Jan-Anders Karlsson, PhD, CEO
Date: Tuesday, August 13th
Time: 1:55 PM EDT
Location: New York, NY
For more information, please visit
https://www.globenewswire.com/Tracker?data=xUde2CJlVoEOYytHu-6Pladtu8PzWnIYTuQEdgr2MUnW4V2wk8Nxo8MB05OkMFOYbAuFCCBbrLtCuucH7pJZ8u12YaeCF_RFKuKjns83IhV_heCqibfGlOFLPoFX9trt
investors.veronapharma.com.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class,
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that
has been shown to act as both a bronchodilator and an anti-inflammatory
agent in a single compound. Nebulized ensifentrine is currently in Phase
2b clinical development for the maintenance treatment of COPD and is
planned to enter Phase 3 trials for this indication in 2020. Verona
Pharma plans a targeted US launch of the nebulized formulation, which is
expected to benefit from a simplified Medicare Part B reimbursement
process in the US. Verona Pharma may also develop ensifentrine for the
treatment of cystic fibrosis and asthma.
Ensifentrine has shown significant and clinically meaningful
improvements in both lung function and COPD symptoms, including
breathlessness, in prior Phase 2 clinical studies in patients with
moderate-to-severe COPD. In addition, ensifentrine has further improved
lung function and reduced lung volumes in patients taking standard
short- and long-acting bronchodilator therapy, including maximum
bronchodilator treatment with dual/triple therapy. Ensifentrine has been
well tolerated in clinical trials involving more than 800 people to
date.
Forward Looking Statements
This press release contains forward-looking statements. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, but not limited to, statements regarding the development
plans for ensifentrine, the timing of Phase 3 trials of nebulized
ensifentrine, the value of the COPD market, the potential of
ensifentrine as a promising first-in-class treatment option for COPD and
the availability of Medicare reimbursement.
These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from our expectations expressed or implied by
the forward-looking statements, including, but not limited to, the
following: our limited operating history; our need for additional
funding to complete development and commercialization of ensifentrine,
which may not be available and which may force us to delay, reduce or
eliminate our development or commercialization efforts; the reliance of
our business on the success of ensifentrine, our only product candidate
under development; economic, political, regulatory and other risks
involved with international operations; the lengthy and expensive
process of clinical drug development, which has an uncertain outcome;
serious adverse, undesirable or unacceptable side effects associated
with ensifentrine, which could adversely affect our ability to develop
or commercialize ensifentrine; potential delays in enrolling patients,
which could adversely affect our research and development efforts and
the completion of our Phase 2b trial; we may not be successful in
developing ensifentrine for multiple indications; our ability to obtain
approval for and commercialize ensifentrine in multiple major
pharmaceutical markets; misconduct or other improper activities by our
employees, consultants, principal investigators, and third-party service
providers; material differences between our "top-line" data and final
data; our reliance on third parties, including clinical investigators,
manufacturers and suppliers, and the risks related to these parties'
ability to successfully develop and commercialize ensifentrine; and
lawsuits related to patents covering ensifentrine and the potential for
our patents to be found invalid or unenforceable. These and other
important factors under the caption "Risk Factors" in our Annual Report
on Form 20-F filed with the Securities and Exchange Commission ("SEC")
on March 19, 2019, and our other reports filed with the SEC, could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of the
date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim any
obligation to do so, even if subsequent events cause our views to
change. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this
press release.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
N+1 Singer Tel: +44 (0)20 3283 4200
(Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Mia Gardner (Corporate Broking)
Optimum Strategic Communications Tel: +44 (0)203 950 9144
(European Media and Investor enquiries) verona@optimumcomms.com
Mary Clark, Anne Marieke Ezendam, Hollie Vile
Westwicke, an ICR Company Tel. +1 646-277-1282
(US Investor enquiries) Stephanie.Carrington@icrinc.com
Stephanie Carrington
(END) Dow Jones Newswires
July 24, 2019 02:00 ET (06:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024